EWTXEdgewise Therapeutics, Inc.

$3B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$38M

Net Income

-$31M

EPS (Diluted)

$-0.34

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$532M

Total Liabilities

$21M

Stockholders' Equity

$510M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$38M	-$25M	-50.4%
Net Income	-$31M	-$21M	-46.7%

EWTX Q2 2024 Earnings — Edgewise Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena